Trial for primary vitreoretinal lymphoma treatment
Part of Cancer clinical trials.
This trial tests a treatment for primary vitreoretinal lymphoma, a rare eye cancer. It aims to see if the drug methotrexate can help patients with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or older
- You have been diagnosed with primary vitreoretinal lymphoma through a biopsy
- You have cancer cells in the fluid of your eye, or had an eye surgery (vitrectomy) to confirm the diagnosis
- You are willing to sign a consent form to join the trial
- You are not allergic to methotrexate
- You are not planning eye surgery during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
This trial compares two treatments for a slow-growing eye lymphoma called MALT lymphoma: a targeted injection (rituximab) directly into the tumor versus low-dose radiation. The goal is to see which is safer and works better, while avoiding whole-body side effects.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial checks how well methotrexate is tolerated in people with primary central nervous system lymphoma. It aims to catch early signs of toxicity to help manage side effects better.
This study compares two treatments for a slow-growing eye lymphoma called MALT lymphoma. One uses a drug called rituximab injected directly into the tumor, and the other uses targeted radiation. The goal is to see which works better with fewer side effects.
Hear when a new Primary Vitreoretinal Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.